Washington, United States | May 1, 2026
Vanda Pharmaceuticals Inc. has announced the U.S. commercial availability of NEREUS™ (tradipitant), marking a historic milestone as the first new pharmacologic treatment for motion sickness in over 40 years. The launch introduces a novel, targeted therapy designed to prevent vomiting associated with motion, addressing a long-standing unmet medical need affecting millions of patients globally. The approval and launch follow strong clinical validation and regulatory clearance, reinforcing innovation in neurokinin-1 (NK-1) receptor antagonist therapies.
First-in-Class Therapy Addresses Unmet Need
The introduction of NEREUS™ (tradipitant) represents a significant advancement in treating motion sickness, a condition affecting an estimated 65 to 78 million Americans, or nearly 30% of adults. For decades, treatment options have remained limited, with no major pharmacologic innovations until now. NEREUS offers a modern mechanism of action by selectively blocking NK-1 receptors, which play a critical role in triggering the vomiting reflex in the brain.
By targeting substance P signaling pathways, the drug interrupts the biological cascade responsible for nausea and vomiting, offering a more precise and effective treatment approach. This innovation is expected to significantly improve patient experience across various travel scenarios, including air, sea, and land transportation, where motion-induced symptoms are prevalent.
Clinical Validation and Regulatory Approval
Advertisement
The FDA approved NEREUS™ on December 30, 2025, based on results from two pivotal Phase 3 clinical trials—Motion SYROS and Motion SERIFOS. These studies were conducted under real-world conditions at sea, demonstrating that the therapy significantly reduced vomiting compared to placebo. The trials provided robust evidence supporting both the efficacy and safety profile of the drug.
NEREUS is administered as an oral capsule taken approximately one hour before travel, offering convenient dosing and improved patient compliance. The therapy is now available through retail pharmacies and a direct-to-consumer platform, ensuring broader accessibility. The drug’s safety profile includes commonly reported side effects such as drowsiness, headache, and fatigue, which are manageable under standard clinical guidance.
Transforming Treatment and Expanding Clinical Potential
The commercial launch of NEREUS signals a new era in motion sickness treatment, with potential implications beyond its initial indication. The drug is currently being explored for additional conditions, including gastroparesis and nausea associated with GLP-1 receptor agonists, highlighting its broader therapeutic potential.
Historically, motion sickness has impacted human performance in critical scenarios, from military operations to space exploration, underscoring the importance of effective treatment solutions. The availability of NEREUS provides a scientifically advanced and clinically validated option, aligning with modern healthcare demands for targeted and patient-centric therapies.
The launch of NEREUS™ (tradipitant) by Vanda Pharmaceuticals marks a breakthrough in the management of motion sickness, offering a first-in-class NK-1 receptor antagonist therapy with strong clinical backing. As the first major innovation in this space in decades, NEREUS is positioned to significantly improve quality of life for millions of patients while advancing the field of neuropharmacology and GxP-regulated drug development.
Source: Vanda Pharmaceuticals press release
